Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy

Table 3 Baseline characteristics of 178 hepatitis B e antigen-positive and 53 hepatitis B e antigen-negative patients with respect to hepatitis B virus DNA response at week 48

	HBeAg-positive (n = 178)			HBeAg-negative (n = 53)
	CVR	PVR	P value	CVR	PVR	P value
	(n = 71)	(n = 107)		(n = 48)	(n = 5)
Age (yr)	32.1 ± 9.9	29.7 ± 8.7	0.09	39.2 ± 10.3	35.2 ± 11.7	0.22
Male n (%)	49 (69)	88 (82)	0.041	29 (72)	6 (46)	0.08
ALT (IU/L)	121 ± 143	107 ± 90	0.108	118 ± 124	120 ± 74	0.89
AST (IU/L)	82 ± 88	56 ± 42	0.0021	73 ± 76	67 ± 92	0.75
PLT (× 109/L)	158 ± 53	175 ± 58	0.05	163 ± 58	181 ± 75	0.97
HBV DNA	7.26 ± 1.05	7.92 ± 0.89	0.0011	6.32 ± 1.29	6.62 ± 0.87	0.15
(log10 IU/mL)
Group A, n (%)	39 (55)	51 (47)	0.34	19 (39)	4 (80)	0.08
FIB-4 index	1.89 ± 1.43	1.18 ± 0.69	0.0011	2.17 ± 1.44	1.92 ± 1.67	0.84

¹This difference was no longer significant after multivariate logistic regression analysis; ²The two groups still showed a significant difference after multivariate logistic regression analysis. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PLT: Platelet; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.